Ruboxyl, a new nitroxyl derivative of daunorubicin

Acute toxicity and antitumor effect in animals

C. Leonetti, T. Aronne, N. Konovalova, R. Diatchkovskaya, A. Shapiro, F. Franchi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Ruboxyl (RBX), a new nitroxyl derivative anthracycline, showed an interesting cytotoxic effect on in vitro established human cell lines and an antitumor activity in tumor-bearing animals. In this study, we further investigated the antitumor effect of this drug compared to Doxorubicin (DX) in four in vivo systems of experimental murine tumors. Our data demonstrate that RBX had little effect on the growth of primary tumor, and on the survival, in mice bearing Lewis lung carcinoma (3LL), while the drug showed a higher effect on the growth of B16 melanoma. In both the experimental murine systems the activity of RBX was similar to that exerted by DX. As regards the leukemia models, RBX induced a significant increase on survival in mice bearing both L1210 or L5178Y leukemias. However, the effect on survival and the number of long-term survivors (LTS) were lower than that observed following DX treatment.

Original languageEnglish
Pages (from-to)615-618
Number of pages4
JournalInternational Journal of Oncology
Volume3
Issue number4
Publication statusPublished - 1993

Fingerprint

Daunorubicin
Doxorubicin
Survival
Leukemia
Lewis Lung Carcinoma
Neoplasms
Experimental Melanomas
Anthracyclines
Growth
Antineoplastic Agents
Survivors
Cell Line
ruboxyl
nitroxyl
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Leonetti, C., Aronne, T., Konovalova, N., Diatchkovskaya, R., Shapiro, A., & Franchi, F. (1993). Ruboxyl, a new nitroxyl derivative of daunorubicin: Acute toxicity and antitumor effect in animals. International Journal of Oncology, 3(4), 615-618.

Ruboxyl, a new nitroxyl derivative of daunorubicin : Acute toxicity and antitumor effect in animals. / Leonetti, C.; Aronne, T.; Konovalova, N.; Diatchkovskaya, R.; Shapiro, A.; Franchi, F.

In: International Journal of Oncology, Vol. 3, No. 4, 1993, p. 615-618.

Research output: Contribution to journalArticle

Leonetti, C, Aronne, T, Konovalova, N, Diatchkovskaya, R, Shapiro, A & Franchi, F 1993, 'Ruboxyl, a new nitroxyl derivative of daunorubicin: Acute toxicity and antitumor effect in animals', International Journal of Oncology, vol. 3, no. 4, pp. 615-618.
Leonetti, C. ; Aronne, T. ; Konovalova, N. ; Diatchkovskaya, R. ; Shapiro, A. ; Franchi, F. / Ruboxyl, a new nitroxyl derivative of daunorubicin : Acute toxicity and antitumor effect in animals. In: International Journal of Oncology. 1993 ; Vol. 3, No. 4. pp. 615-618.
@article{c67f82ce83f54b2bb389b5445ea524ef,
title = "Ruboxyl, a new nitroxyl derivative of daunorubicin: Acute toxicity and antitumor effect in animals",
abstract = "Ruboxyl (RBX), a new nitroxyl derivative anthracycline, showed an interesting cytotoxic effect on in vitro established human cell lines and an antitumor activity in tumor-bearing animals. In this study, we further investigated the antitumor effect of this drug compared to Doxorubicin (DX) in four in vivo systems of experimental murine tumors. Our data demonstrate that RBX had little effect on the growth of primary tumor, and on the survival, in mice bearing Lewis lung carcinoma (3LL), while the drug showed a higher effect on the growth of B16 melanoma. In both the experimental murine systems the activity of RBX was similar to that exerted by DX. As regards the leukemia models, RBX induced a significant increase on survival in mice bearing both L1210 or L5178Y leukemias. However, the effect on survival and the number of long-term survivors (LTS) were lower than that observed following DX treatment.",
author = "C. Leonetti and T. Aronne and N. Konovalova and R. Diatchkovskaya and A. Shapiro and F. Franchi",
year = "1993",
language = "English",
volume = "3",
pages = "615--618",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Ruboxyl, a new nitroxyl derivative of daunorubicin

T2 - Acute toxicity and antitumor effect in animals

AU - Leonetti, C.

AU - Aronne, T.

AU - Konovalova, N.

AU - Diatchkovskaya, R.

AU - Shapiro, A.

AU - Franchi, F.

PY - 1993

Y1 - 1993

N2 - Ruboxyl (RBX), a new nitroxyl derivative anthracycline, showed an interesting cytotoxic effect on in vitro established human cell lines and an antitumor activity in tumor-bearing animals. In this study, we further investigated the antitumor effect of this drug compared to Doxorubicin (DX) in four in vivo systems of experimental murine tumors. Our data demonstrate that RBX had little effect on the growth of primary tumor, and on the survival, in mice bearing Lewis lung carcinoma (3LL), while the drug showed a higher effect on the growth of B16 melanoma. In both the experimental murine systems the activity of RBX was similar to that exerted by DX. As regards the leukemia models, RBX induced a significant increase on survival in mice bearing both L1210 or L5178Y leukemias. However, the effect on survival and the number of long-term survivors (LTS) were lower than that observed following DX treatment.

AB - Ruboxyl (RBX), a new nitroxyl derivative anthracycline, showed an interesting cytotoxic effect on in vitro established human cell lines and an antitumor activity in tumor-bearing animals. In this study, we further investigated the antitumor effect of this drug compared to Doxorubicin (DX) in four in vivo systems of experimental murine tumors. Our data demonstrate that RBX had little effect on the growth of primary tumor, and on the survival, in mice bearing Lewis lung carcinoma (3LL), while the drug showed a higher effect on the growth of B16 melanoma. In both the experimental murine systems the activity of RBX was similar to that exerted by DX. As regards the leukemia models, RBX induced a significant increase on survival in mice bearing both L1210 or L5178Y leukemias. However, the effect on survival and the number of long-term survivors (LTS) were lower than that observed following DX treatment.

UR - http://www.scopus.com/inward/record.url?scp=0027449259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027449259&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 615

EP - 618

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -